AFDN and breast carcinoma: Afadin is phosphorylated at serine 1718 by Akt, which is activated in response to insulin-like growth factor-1, or by oncogenic alterations in the phosphatase and tensin homolog–PI3K–Akt pathway, and translocated into the nucleus, disrupting the AJs and enhancing migration in breast cancers (64).